Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
Public ClinicalTrials.gov record NCT04586023. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Multicenter Randomized, Double-blind, Double-dummy, Parallel-group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Adult Patients With Relapsing Multiple Sclerosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS. Eligible participants will be randomized in a 1:1 ratio to receive either fenebrutinib or teriflunomide. At the end of the double-blind treatment (DBT) phase (after disclosure of the DBT results), the Sponsor will determine whether or not to initiate the open-label extension (OLE) phase of the study.
Study identification
- NCT ID
- NCT04586023
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 751 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 24, 2021 (Actual)
- Primary completion
- Sep 5, 2025 (Actual)
- Completion
- Jul 9, 2027 (Estimated)
- Last update posted
- Sep 17, 2026
2021 – 2027
United States locations
- U.S. sites
- 12
- U.S. states
- 12
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| North Central Neurology Associates | Cullman | Alabama | 35058 | — |
| Xenoscience | Phoenix | Arizona | 85004 | — |
| Los Angeles Biomedical Research Institute at Harbor-UCLA | Torrance | California | 90502 | — |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 20007 | — |
| University of South Florida | Tampa | Florida | 33612 | — |
| American Health Network Institute, LLC | Avon | Indiana | 46123 | — |
| University of Kansas Medical Center | Kansas City | Kansas | 66160 | — |
| Neuro Institute of New England P.C. | Foxborough | Massachusetts | 02035 | — |
| University of Cincinnati | Cincinnati | Ohio | 45219 | — |
| Hope Neurology | Knoxville | Tennessee | 37922 | — |
| Integrated Neurology Services PLLC | Falls Church | Virginia | 22043 | — |
| Medical College of Wisconsin, Inc. | Milwaukee | Wisconsin | 53226-3596 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 94 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04586023, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 17, 2026 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04586023 live on ClinicalTrials.gov.